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utable to nasal congestion are substantial. These high costs
emphasize the importance of diagnosing and treating nasal
congestion.
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OBJECTIVE: To determine the incremental direct medical
expenditures of treating adult asthma in the United States.
METHODS: Retrospective analysis was conducted using the
2004 Medical Expenditure Panel Survey (MEPS) data. Adult
asthma respondents (age 18 years; n = 1552) were identiﬁed
as those with International Classiﬁcation of Diseases (ICD)-9
diagnosis codes for asthma or those that self-reported as having
asthma in 2004. Incremental total expenditures and expendi-
tures for various categories of resource use, i.e., physician ofﬁce
visits, emergency room visits, outpatient visits, inpatient visits,
medications and other medical expenses associated with
asthma, were estimated using separate multivariate regression
models. The models were adjusted for age, gender, race, ethnic-
ity, education, marital status, geographic region, insurance
status and comorbidities (using the Charlson comorbidity
index). Given the skewed distribution of expenditure variables,
multiple model speciﬁcations including ordinary least squares
regression, generalized linear model (GLM) with Poisson,
gamma and negative binomial variance functions were evalu-
ated. RESULTS: The prevalence of current asthma among
adults in 2004 was estimated at 6.84%, i.e., 14.9 million
persons (95% CI: 6.43% to 7.26%) in the United States. Indi-
viduals with asthma had 68% higher total expenditures than
non-asthmatics after controlling for covariates (RR: 1.68;
p < 0.0001). The annual adjusted mean incremental total expen-
diture associated with asthma was $1953.7 (SE: $500.1; p
<0.0001) per person. Medications accounted for the largest pro-
portion of the total expenditures estimated at $609.4 (SE:
$52.0; p <0.0001), followed by physician ofﬁce visits at $364.3
(SE: $86.9; p <0.0001) and inpatient visits at $297.3 (SE:
$191.2; p = 0.074). CONCLUSION: Given the prevalence of
adult asthma and its associated incremental expenditures, the
annual direct medical expenditure for treating adult asthma is
estimated at $29.2 billion in 2005 USD. This estimated incre-
mental expenditure associated with asthma is more than twice
the cost of asthma reported in previous studies.
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OBJECTIVE: To review up-to-date economic outcomes data in
patients with cystic ﬁbrosis (CF), especially costs related to res-
piratory infection by Pseudomonas aeruginosa (Pa), the leading
cause of morbidity and mortality in CF patients. METHODS: A
systematic search of the MEDLINE database from 1990–2007
was conducted, using the terms “cystic ﬁbrosis” and “cost.”
Selected conference abstracts were also searched. Recent articles
that contained economic data on antibiotic and mucolytic thera-
pies were selected for in-depth review. RESULTS: In-depth
review was performed on 27 articles that examined the economic
impact of inhaled tobramycin (2 articles), the effect of home- vs.
hospital-based antibiotic therapies for pulmonary exacerbations
(4), economic impact of recombinant human deoxyribonuclease
(rhDNase) (10), and cost-of-illness for CF (11). Inhaled tobra-
mycin led to reductions in health care costs that offset 37%–57%
of the drug cost. Home-based antibiotic therapy for exacerba-
tions generally resulted in lower health care costs than hospital-
based administration. Use of rhDNase led to reductions in health
care costs that offset 17%-38% of the drug cost. Cost-of-illness
studies have been conducted in 7 countries; the economic esti-
mates varied widely ($9,000 to $64,000/patient/year; 2006 US
dollars) due to differences in treatment patterns, health systems,
methodologies, and subjects. Most cost-of-illness studies were
retrospective observational studies of direct costs from the per-
spective of a hospital or third-party payer. The largest cost cat-
egories included hospitalizations, out-patient visits, rhDNase and
antibiotics. Disease severity and Pa infection were major deter-
minants of cost. CONCLUSION: Studies show that inhaled
tobramycin and rhDNase partially offset medical costs; home-
based antibiotic therapy likely reduces costs; and direct costs can
be high but vary widely across countries and analytical method-
ologies. Areas for future research include direct comparisons of
inhaled antibiotic therapies, examination of the relationship
between treatment adherence and economic outcomes, and esti-
mation of societal cost-of-illness.
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OBJECTIVE: To conduct a cost-utility analysis by comparing
two scenarios in Japan: smoking cessation counseling by a phy-
sician versus use of varenicline, an oral smoking cessation drug,
in addition to counseling. METHODS: A Markov model was
constructed to analyse life-time medical costs and Quality-
Adjusted Life Years (QALYs) from the perspective of health care
payers. In the Markov model, ﬁve years were set as one cycle.
Both cost and utility were discounted at 3% annually. The cohort
of smokers was classiﬁed by gender and age, and we assumed
that smokers started smoking aged 20 years and received
smoking cessation therapy aged 30, 40, 50, 60, or 70 years. The
health care cost and QALYs were calculated throughout the
term until 90 years. We chose three parameters for sensitivity
analyses—success rate of varenicline, unit price of varenicline
and discount rate. In the base-case analysis, success rates of
varenicline and placebo were assumed to be 37.9% and 25.5%,
respectively, in male smokers, and 22.2% and 16.1%, respec-
tively, in female smokers, based on a randomized controlled trial
conducted in Japan. We chose QALY for outcome measurement.
Quality weight for each tobacco-associated disease was derived
from the literature. RESULTS: It was shown that the scenario
where varenicline was prescribed is more effective and less costly
than giving smoking cessation counseling alone. Varenicline
would save direct medical costs of JPY 26,000 (USD226,
USD1 = JPY115) and increase 0.094 QALY in male smokers.
Regarding the budget impact, varenicline is estimated to save JPY
23.7 billion (USD 206 million) of the medical costs for tobacco-
associated diseases for the whole population. Sensitivity analyses
suggested the robustness of the results. CONCLUSION: Vareni-
cline, the ﬁrst oral treatment for smoking cessation in Japan, is
cost-effective and will contribute to the reduction of medical
costs.
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